Kestra Private Wealth Services LLC Sells 5,971 Shares of Sanofi (NASDAQ:SNY)

Kestra Private Wealth Services LLC reduced its position in shares of Sanofi (NASDAQ:SNY) by 23.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 19,604 shares of the company’s stock after selling 5,971 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Sanofi were worth $946,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Synergy Asset Management LLC bought a new stake in Sanofi in the 4th quarter valued at $25,000. Northwest Investment Counselors LLC bought a new stake in Sanofi in the 3rd quarter valued at $29,000. Concord Wealth Partners boosted its holdings in Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares during the period. Fortitude Family Office LLC boosted its holdings in Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after purchasing an additional 659 shares during the period. Finally, Sunbelt Securities Inc. boosted its holdings in Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares during the period. 14.04% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

SNY has been the subject of a number of research reports. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Sanofi presently has a consensus rating of “Buy” and an average price target of $60.00.

Sanofi Price Performance

Shares of Sanofi stock opened at $53.99 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.74 and a current ratio of 1.46. The firm’s 50-day simple moving average is $50.18 and its 200-day simple moving average is $52.42. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The firm has a market cap of $137.02 billion, a P/E ratio of 21.68, a price-to-earnings-growth ratio of 0.99 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. As a group, research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.